Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
about
Calsequestrin 2 and arrhythmiasMechanisms of ranolazine's dual protection against atrial and ventricular fibrillationCa2+ Sparks and Ca2+ waves are the subcellular events underlying Ca2+ overload during ischemia and reperfusion in perfused intact hearts.Channel Activity of Cardiac Ryanodine Receptors (RyR2) Determines Potency and Efficacy of Flecainide and R-Propafenone against Arrhythmogenic Calcium Waves in Ventricular CardiomyocytesFlecainide: Current status and perspectives in arrhythmia managementParadoxical effect of increased diastolic Ca(2+) release and decreased sinoatrial node activity in a mouse model of catecholaminergic polymorphic ventricular tachycardia.Impact of detubulation on force and kinetics of cardiac muscle contraction.Essential Role of Calmodulin in RyR Inhibition by Dantrolene.Accelerated junctional rhythm and nonalternans repolarization lability precede ventricular tachycardia in Casq2-/- mice.Ryanodine receptor inhibition potentiates the activity of Na channel blockers against spontaneous calcium elevations and delayed afterdepolarizations in Langendorff-perfused rabbit ventricles.In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.Flecainide reduces Ca(2+) spark and wave frequency via inhibition of the sarcolemmal sodium current.A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.Phospholamban knockout breaks arrhythmogenic Ca²⁺ waves and suppresses catecholaminergic polymorphic ventricular tachycardia in mice.Suppression of spontaneous ca elevations prevents atrial fibrillation in calsequestrin 2-null hearts.Divergent regulation of ryanodine receptor 2 calcium release channels by arrhythmogenic human calmodulin missense mutants.Murine Electrophysiological Models of Cardiac Arrhythmogenesis.Effect of flecainide derivatives on sarcoplasmic reticulum calcium release suggests a lack of direct action on the cardiac ryanodine receptor.Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts.Triple mode of action of flecainide in catecholaminergic polymorphic ventricular tachycardia.Reply from Pei-Chi Yang, Jonathan D. Moreno, Mao-Tsuen Jeng, Xander H. T. Wehrens, Sergei Noskov and Colleen E. Clancy.Beneficial effects of leptin treatment in a setting of cardiac dysfunction induced by transverse aortic constriction in mouse.Computational Modeling of Electrophysiology and Pharmacotherapy of Atrial Fibrillation: Recent Advances and Future Challenges
P2860
Q24300626-FA19CD61-8664-4BE2-8596-0D564701F958Q26995558-DD42B5A9-30F0-4276-A3AB-850FB196C60BQ27302397-4633A9FC-21F4-44DC-B29C-1273A6ADA277Q27303698-916B07E0-8753-4C10-8179-2026D47991D4Q28081935-3C955213-D6ED-42C7-9F62-E2EA745FFFE5Q33161429-154A896D-1A30-4BC3-8D5F-085EB3DF348BQ33672949-1A69859F-651F-469F-9556-AB8B1828F6EDQ35745969-8A1E88FA-1B30-4919-8ECB-098F68CAC74DQ36381286-4B554D93-883B-4FEC-82B1-819286713FBEQ36610682-C82AE3B8-A453-4A1D-96B6-327A88C6ED3BQ36667578-2B2C3F44-E8E8-431B-9E0C-6D919166414AQ37023408-D9314CC9-035D-43D5-BA49-521E038E52E9Q37305886-52E88BD3-41CF-49FF-BC77-1798E418D1C2Q37396106-794317DD-540D-490F-869B-5AF8C3E1AC2DQ37707108-E4974E78-FCC6-41B0-9CDE-9F0B40B48CCAQ37708601-6FF7E1F8-1768-4B03-87FE-854E4833C74CQ39038606-BA9DED97-5F55-489B-B0F8-47750425B5F2Q39727420-FE5AEBB0-29AA-4599-B6A4-56357697C201Q41910718-5828C07E-63D2-4580-9329-F9C8B90A90E4Q43158949-26A5F506-3CBC-4D92-AE11-BD74B33797DBQ46137231-84F19BD0-BFFE-4464-B880-E185EF29C3C9Q48325152-579879A8-8793-4261-BAA9-E9B07ADCF4F7Q57161239-D244C96B-E0EA-42D8-AA61-70761AE09863
P2860
Efficacy and potency of class I antiarrhythmic drugs for suppression of Ca2+ waves in permeabilized myocytes lacking calsequestrin.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Efficacy and potency of class ...... yocytes lacking calsequestrin.
@en
type
label
Efficacy and potency of class ...... yocytes lacking calsequestrin.
@en
prefLabel
Efficacy and potency of class ...... yocytes lacking calsequestrin.
@en
P2860
P1476
Efficacy and potency of class ...... myocytes lacking calsequestrin
@en
P2093
Eleonora Savio Galimberti
P2860
P304
P356
10.1016/J.YJMCC.2011.07.002
P577
2011-07-12T00:00:00Z